Feasibility and Acceptability of HCV Treatment in Pregnancy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorWashington University School of Medicine
About this trial
Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use
Participant Duration: Approximately 1 year.
Aims:
Aim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs.
Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.
Eligibility criteria
Qualifiers
Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Glecaprevir-pibrentasvir
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov